

09/509775

422 Rec'd T/PTO 31 MAR 2000

Sheet 1 of 1

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0277	SERIAL NO. Unassigned		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT		Jun FUJITA			
		FILING DATE		GROUP ART UNIT Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
✓	A1	9-75085	03/1997	Japan			Abstr.
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
NAD	A2	* Willardson, et al. "Localization of the Ankyrin-binding Site of Erythrocyte Membrane Protein, Band 3," J. Biol. Chem., Vol. 264, No. 27, pp. 15893-15899 (1989)					
NAD	A3	DeCaprio, et al., "The Product of the Retinoblastoma Susceptibility Gene Has Properties of a Cell Cycle Regulatory Element," Cell, Vol. 58, No. 6 pp. 1085-1095 (1989)					
NAD	A4	Baeuerle, et al. "Activation of DNA-Binding Activity in an Apparently cytoplasmic Precursor of the NF-K B Transcription Factor," Cell, Vol. 53, No. 2, pp 211-217 (1988)					
EXAMINER <i>Not Livedow</i>				DATE CONSIDERED 8-31-01			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0277	SERIAL NO. 09/509,775
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT		Jun FUJITA	
		FILING DATE 03/31/2000		GROUP ART UNIT 1643	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
O I P E	JCT						

FOREIGN PATENT DOCUMENTS							
PATENT & TRADEMARK OFFICE	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		A1	9-075085	03/97	JAPAN		Abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

N/A ✓	A2	*FURUTANI et al.; "Decreased Expression and Rare Somatic Mutation of the CIPI/WAF1 Gene in Human Hepatocellular Carcinoma"; Cancer Letters; 1997; pp. 191-197.
	A3	*WILLARDSON et al.; "Localization of the Ankyrin-binding Site on Erythrocyte Membrane Protein Band 3"; The Journal of Biological Chemistry; Vol. 264, No. 27; September 25, 1989; pp. 15893-15899.
	A4	*DECAPRIO et al.; "The Product of the Retinoblastoma Susceptibility Gene Has Properties of A Cell Cycle Regulatory Element"; Cell; Vol. 58; September 22, 1989; pp. 1085-1095.
	A5	*BAEUPERLE et al.; "Activation of DNA-Binding Activity In An Apparently Cytoplasmic Precursor of the NF- κ B Transcription Factor"; Cell; Vol. 53; April 22, 1988; pp. 211-217.
	A6	*TOBE et al.; "Prime Liver Cancer in Japan"; 1992; pp. 445-453.
	A7	*TOBE et al.; "Prime Liver Cancer in Japan"; 1992; pp. 243-255.
	A8	*FURUTANI et al.; "Kan-1 (Bile Acid CoA:Amino Acid N-Acyltransferase) Messenger RNA as a Novel Predictive Indicator for Prognosis of Hepatocellular Carcinoma Patients After Partial Hepatectomy"; Hepatology; Vol. 24, No. 6; 1996; pp. 1441-1445.
	A9	*TOBE et al.; "Prime Liver Cancer in Japan"; 1990; pp. 277-287.
	A10	*BELGHITI et al.; "Intrahepatic Recurrence After Resection of Hepatocellular Carcinoma Complicating Cirrhosis"; Ann. Surg.; Vol. 214, No. 2; August 1991; pp. 114-117.
	A11	*MISE et al.; "Clinical Significance of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Gene Expression in Liver Tumor"; Hepatology; Vol. 23, No. 3; March 1996; pp. 455-464.
	A12	*CALVET et al.; "Prognostic Factor of Hepatocellular Carcinoma in the West: A Multivariate Analysis in 206 Patients"; Hepatology; Vol. 12, No. 4; 1990; pp. 753-760.
	A13	*FRANCO et al.; "Resection of Hepatocellular Carcinomas"; Gastroenterology; Vol. 98, No. 3; 1990; pp. 733-738
	A14	*TOBE et al.; "Predictive Factors for Long Term Prognosis After Partial Hepatectomy for Patients With Hepatocellular Carcinoma in Japan"; Cancer; Vol. 74, No. 10; 1994; pp. 2772-2775.

EXAMINER	<i>Notable Order</i>	DATE CONSIDERED	<i>8/29/01</i>
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>			